[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

FirstWord: Market Research Reports

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:

  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.


FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Publications found: 700
Sort by:

Physician Views: Can Bayer deliver on its Xarelto bullishness?

US$ 695.00

... of warfarin) with Xarelto retaining its current level of market share. Bayer's confidence in Xarelto is clearly high, adds Leuchten, pointing to the ... this week's Physician Views poll revisits the novel anticoagulant market and surveys cardiologists and general practioners/primary care physicians (GP/PCPs) ...

March 2014

The Reality of Market Access in Europe: the role of Health Technology Assessment

US$ 595.00

... early stages of being coordinated into a system across Europe. In The Reality of Market Access in Europe: the role of Health Technology Assessment, FirstWord skilfully addresses ... Benefits Attitudes to drug reimbursement have been shaped by economics. In The Reality of Market Access in Europe: the role of Health Technology Assessment, you will: Understand ...

March 2014 82 pages

Physician Views: What role will device development play in the future GLP-1 agonist market?

US$ 695.00

... will provide payers to extract greater discounting and rebates – will also play a role in market development. Nevertheless, AstraZeneca is hoping that a new pen device will ... and/or patient preference towards this drug class as a whole? What advantage they perceive would be provided by an auto-injector pen ...

March 2014

Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?

US$ 695.00

... available (its approval in the US market is anticipated in Q3). Predicting an accurate view of future market dynamics remains difficult at this point, however ... expect to prescribe a once-weekly product with comparable efficacy to Victoza (i.e. dulaglutide) if that product had: A comparable weight-loss profile; ...

March 2014

Diabetes - KOL Insight and Consensus Outlook Modules

US$ 7,495.00

... term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels ... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive ...

February 2014 224 pages

Physician Views: A closer look at Gilead's spectacular Sovaldi launch

US$ 695.00

... accounted for around 70 percent of usage to date. Genotype 1 patients are viewed as being a key population for all-oral therapies (which dispense ... availability may have on new patient diagnosis rates. This week's Physician Views poll asks US and EU-based gastroenterologists, hepatologists and infectious disease ...

February 2014

Value-driven Pharma: Integrating health outcomes across the product lifecycle

US$ 595.00

... pharma companies truly integrating health outcome values into product development or merely paying lip-service? In a rare and comprehensive insight into thriving in the "Outcomes Era", Value-driven Pharma: Integrating health outcomes across ... been shaped by economics. In Value-driven Pharma: Integrating health outcomes across the product lifecycle, you will: Understand the importance of endorsing a comprehensive approach to health outcomes from the earliest ...

February 2014 44 pages

Stakeholder Perspectives: Innovation within the Biopharma Industry

US$ 2,495.00

... all of the ‘low hanging fruit’ have been taken there is another perspective: that there is plenty of fruit left on the tree and companies ... company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment ...

February 2014 99 pages

Breast Cancer: New targeted therapies transform treatment - KOL Insight

US$ 7,495.00

... opinion This new KOL Insight report Breast Cancer –new targeted therapies transform treatment provides everyone interested in this dynamic cancer sector with a complete understanding of the targeted products ... and weaknesses of currently available targeted therapies for breast cancer Assess how prescribing trends will change with launch of new products Identify promising late-stage ...

February 2014 153 pages

Physician Views: Biosimilar naming conventions – what do physicians think?

US$ 695.00

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

February 2014

Physician Views: How will neurologists embrace Teva's new version of Copaxone? What about potential generic versions later this year?

US$ 695.00

... using it for a long time with no real safety issues." How neurologists utilise any generic version of Copaxone, should one or multiple ... about potential usage of such a product. This week's Physician Views poll will ask US-based neurologists: Approximately what percentage of existing Copaxone patients do you ...

February 2014

Physician Views: How do Indian oncologists plan to use biosimilar Herceptin?

US$ 695.00

... to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will ... drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size ...

January 2014

Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta

US$ 695.00

... a notable caveat could be that it is waiting to step up promotion of Breo when it launches a second new COPD drug – Anoro Ellipta – which was approved ... has delivered lower-than-expected uptake since launching in late 2013, this week's Physician Views poll will ask US-based pulmonologists: Approximately how ...

January 2014

Physician Views: As momentum grows for the SGLT-2 inhibitor class, can AstraZeneca's Farxiga move into Invokana's slipstream?

US$ 695.00

... to be seen if Farxiga can find a suitable position in Invokana's slipstream. While physicians have embraced the SGLT-2 class – with sizeable usage reported ... to side-effect concerns) could also limit uptake. Nevertheless, with momentum growing for the SGLT-2 class, there could be an opportunity for AstraZeneca ...

January 2014

Designing Clinical Trials to Show Value

US$ 595.00

... is changing. In Designing Clinical Trials to Show Value, you will: Understand how new concepts of value created by cost-conscious healthcare stakeholders are transforming clinical development programmes ... Understand new trends in clinical trials that promise to deliver product value sought by regulators, health systems and patients Designing Clinical Trials to Show Value answers key questions ...

December 2013 63 pages

Effective Pharma KAM Teams - the essential factors driving performance

US$ 595.00

... . This report breaks down KAM requirements and lets you build the team you need. This new report Effective Pharma KAM Teams – the essential factors driving performance provides everyone involved with building running or implementing KAM ...

December 2013 52 pages

Market Access for Orphan Drugs: assessing the global landscape

US$ 595.00

... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...

November 2013 100 pages

Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook

US$ 7,495.00

... effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that ... significant market event. Key Benefits Therapy Trends Consensus Outlook: Hepatitis C provides: Evaluate future sales forecasts and predicted market growth ...

November 2013

Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?

US$ 695.00

... radiopharmaceutical - see In Focus: Bayer's M&A catalyst – FirstWord speaks to Xofigo's lead investigator. Impressive Q3 sales, and confirmation that Bayer and Algeta ... gain a better understanding of the outlook for Xofigo, this week's Physician Views poll will ask US-based urologists and oncologists... Where ...

November 2013

Physician Views: Sanofi's successor to Lantus - are endocrinologists impressed?

US$ 695.00

... hypoglycaemia – currently known as Insulin U300 – is the most important product in Sanofi's late-stage R&D pipeline. With submission to regulators expected next year ... in selected European markets and Japan – there appears to be an opportunity for Sanofi to push home an advantage with U300, particularly by building on the entrenchment ...

November 2013

Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?

US$ 695.00

... currently anticipated for AbbVie. To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious ... of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed ...

November 2013

Physician Views: What opportunity for Novo Nordisk's Victoza in obesity?

US$ 695.00

... mixed opinions on the commercial opportunity, but one of the more intriguing near- ... the US within the next few months, this week's Physician Views poll targets general practitioners and internal ... obesity (and based on available Phase III data), in what percentage of obese patients would you consider prescribing ...

November 2013

Physician Views: Oncologist reaction to Roche's Gazyva – US approval and new late-stage data versus Rituxan

US$ 695.00

... for Gazyva are ongoing. This week’s FirstWord Physician Views poll aims to gauge initial oncologist reaction to the data for, and approval of, Gazyva and ... uptake will occur in the first-line CLL setting. Specifically oncologists based in the US and EU5 will be asked: What percentage of chronic ...

November 2013

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

US$ 7,495.00

... the global prostate cancer market to grow from $3.5 billion in 2012 to $7.7 billion in 2017. Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top analyses the global prostate cancer market players ... data analysis updates over the next 12 months Report Benefits: Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top will allow you to: Evaluate future ...

October 2013

Commercialisation of Biosimilars: strategies for market penetration

US$ 595.00

... world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned. In Commercialisation of Biosimilars: strategies for ... of how to design strategies to influence key opinion leaders Understand why biosimilar acceptance is slower than most new generic drugs Commercialisation of Biosimilars: strategies for market penetration ...

October 2013 124 pages

Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?

US$ 695.00

... opinion leader feedback. Similarly, there is evidence to support the view that anticipation among European neurologists is equally high. When ... Delayed launch for Biogen Idec's Tecfidera said to be causing 'quasi-hysteria' among European MS patients). With Tecfidera now approaching what appears to be a critical ...

October 2013

Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)

US$ 595.00

... ’s a revolution happening...and it’s going to change the way pharma thinks. As the accountable care movement gains traction in the United States and physicians eye a possible ... in the face of revolution, pharma must first understand the complete scope of the change now underway. In Pharma and the Changing US Payer Environment: Meeting the ...

October 2013 71 pages

Physician Views: How have cardiologists, internal medicine specialists and general practitioners reacted to the new AHA/ACC cholesterol management guidelines

US$ 695.00

... Key questions focus on how enthusiastically the guidelines will be embraced by physicians and how rapidly. In a note to ... the PCSK9 inhibitors, a number of analysts have pointed out, however, that initial ... inhibitors. This week’s Physician Views poll will ask US-based cardiologists, general practioners and ...

October 2013

Physician Views: Revisiting Pfizer's Xeljanz – is the oral revolution gaining traction in rheumatoid arthritis?

US$ 695.00

... Xeljanz to gain approval in Europe (see ViewPoints: Key opinion leader casts doubt as to whether Pfizer's Xeljanz ... Xeljanz's ability to inhibit progression of structural disease. FirstWord polled US-based rheumatologists in May to ascertain how physicians were utilising Xeljanz and this week's Physician Views ...

October 2013

Market Access Collection

US$ 4,095.00

The collection includes the following reports: Market Access Canada Market Access in the EU5 – a comparative overview Value-based Key Account Management and the NHS – ensuring optimal performance under new rules Biosimilars in Emerging Markets

October 2013

Marketing Collection

US$ 6,495.00

The collection includes the following reports: Pharma and Gamification: motivating positive outcomes – a primer The Impact of Mobile Health on Patient-Centric ... real-world commercial benefit from closed-loop marketing Driving Brand Value in Emerging Markets - winning strategies and tactics Big Data ...

October 2013

Medical Affairs Collection

US$ 2,295.00

The collection includes the following reports: MSL-KOL Engagement: delivering value under new rules Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value The Path to Product Inclusion in Clinical Guidelines: Strategies for Success ...

October 2013

Generics/Biosimilars Collection

US$ 4,595.00

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

October 2013

Emerging Markets Collection

US$ 3,295.00

The collection includes the following reports: Inside China’s Pharma Sales Force – insights from the frontline Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets Driving Brand Value in Emerging Markets - winning strategies and tactics

October 2013

Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

US$ 7,495.00

The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains ... , products, late-stage pipeline drugs, product positioning, in the context of COPD market trends. Event Bulletins Benefit from the latest KOL ...

September 2013 157 pages

Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them?

US$ 695.00

... be done to improve how these predictive tools can be used? This week's Physician Views poll asks oncologists based in the US and 5EU markets: How many cancer patients they assess with a companion diagnostic prior to treatment? How the ...

September 2013

Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?

US$ 695.00

... demonstrated when administered in combination with statin therapy. Given the entrenchment (and genericisation) of most statin therapies, coupled with the subcutaneous ... potential for the emergent PCSK9 inhibitor class. This week's Physician Views poll asks US and 5EU-based cardiologists and general ...

September 2013

Physician Views: The great generic Advair opportunity – a physician perspective

US$ 695.00

... the second pharmacy benefits manager to do so (after CVS Caremark) - see Physician Views Poll Results – US Pulmonologists keen for Breo Ellipta – can payers ... device. This week's Physician Views poll asks pulmonologists and general practitioners based in the US and 5EU markets (where a substitutable generic version of Advair ...

September 2013

Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?

US$ 695.00

... or ribavirin, thus significantly reducing side-effect burden. A Physician Views poll run by FirstWord in December 2012 (among 74 US-based gastroenterologists ... one-tablet combination of sofosbuvir and ledipasvir). But what of its commercial opportunity in the meantime, assuming the drug is launched in ...

September 2013

Colorectal Cancer - KOL Insight Module

US$ 7,495.00

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in ... clinical opinion This new KOL Insight report Colorectal Cancer - EGFR inhibitors on the verge of growth provides everyone interested in this dynamic cancer sector with a complete ...

September 2013 127 pages

Strategies for Working With Real World Data

US$ 395.00

... that is, increasingly, transforming healthcare into ‘reality medicine’ that responds to the real world use of medicines rather than that prescribed by randomised controlled ... to pricing and positioning. How should pharma respond? In Strategies for Working with Real World Data, FirstWord makes a strong case for ...

September 2013 61 pages

Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?

US$ 695.00

... a cost of up to $1 billion. This week's Physician Views poll will look to assess whether initial KOL and analyst reaction to the top-line PREVAIL ... to prescribe enzalutamide (Xtandi) to on an off-label basis prior to approval? What characteristic would most influence you to prescribe enzalutamide (Xtandi) in ...

September 2013

Consensus Outlook: Multiple Sclerosis

US$ 7,495.00

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary ... efficacious therapy, and continued uptake of existing therapies. Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and ...

August 2013 35 pages

Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU

US$ 695.00

... collectively as the ABCRs), which for many years were positioned as the gold standard therapies of choice - see Physician Views Poll Results – Neurologists ... analysts, which Novartis and Sanofi will no doubt do their best to rectify. Analysts at Barclays recently noted that 'importantly, the multiple sclerosis ...

August 2013

Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

US$ 695.00

... Ingelheim's Pradaxa was not a widely held view FirstWord Pharma PLUS subscribers can view the results and analysis from this poll ... . This week's FirstWord Physician Views poll will ask: How do the clinical profiles of oral anticoagulants compare with warfarin? How does the clinical profile ...

August 2013

Physician Views – Sanofi's no-go decision on lixisenatide monotherapy sharpens focus on GLP-1/insulin combination products – what are the expectations of GPs, endocrinologists based in the US, 5EU?

US$ 695.00

... of a combination Lantus/lixisenatide product, but commercial opportunity significant. Sanofi has previously demonstrated a willingness to shift its development strategy ... of Lantus in the long-acting insulin market. This week's Physician Views poll will ask endocrinologists and general practioners based in ...

August 2013

Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?

US$ 695.00

... Sanofi securing European approval for its multiple sclerosis ... therapies (Gilenya, Aubagio and Tecfidera – yet to launch in Europe) providing comparable efficacy with greater convenience, there is ... patients using the drug developing PML. This week's Physician Views poll will ask neurologists based in the 5EU ( ...

August 2013

Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight

US$ 4,995.00

... ; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma. Competition in the major ... market share from the gold standard treatments. ‘Therapy Trends: Diabetes’ is compiled from exclusive, in-depth interviews with the world’s leading ...

July 2013

Innovations in Multichannel Marketing

US$ 595.00

... centricity, patient empowerment, and closed-loop marketing (CLM). Innovations in Multichannel Marketing is a must-read for forward-thinking marketing and sales professionals. Key Benefits With ... a multichannel world for pharma.” – John Gerow, European multi-channel marketing director, AstraZeneca Innovations in Multichannel Marketing addresses your strategic and tactical questions, such as: What is multichannel marketing ...

July 2013 55 pages

The Impact of Mobile Health on Patient-Centric Disease Management

US$ 595.00

... trials. Through The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores the emerging and exciting world of mobile and digital health apps. Based ... , Boehringer Ingelheim. The Impact of Mobile Health on Patient-Centric Disease Management answers key questions: How can pharma harness the mobile and digital app ...

July 2013 105 pages

Filters

Search

Categories

1
43
3
2
3
2
1
16
1
1
8
2
4
1
19
1
1
1
2
31
6
24
62
10
455

Publishers

700

Regions

2
1
15
1
1
14
4
1
660
1

Price

Date

Pages

Offers